NASDAQ:NPCE NeuroPace (NPCE) Stock Forecast, Price & News $9.73 +0.42 (+4.51%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$8.99▼$9.7350-Day Range$4.00▼$9.7352-Week Range$1.22▼$9.73Volume35,017 shsAverage Volume59,858 shsMarket Capitalization$251.62 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media NeuroPace MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside17.8% Downside$8.00 Price TargetShort InterestHealthy3.33% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.53) to ($1.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.66 out of 5 starsMedical Sector869th out of 972 stocksSurgical & Medical Instruments Industry86th out of 96 stocks 1.3 Analyst's Opinion Consensus RatingNeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, NeuroPace has a forecasted downside of 17.8% from its current price of $9.73.Amount of Analyst CoverageNeuroPace has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.33% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in NeuroPace has recently decreased by 20.15%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuroPace does not currently pay a dividend.Dividend GrowthNeuroPace does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NPCE. Previous Next 2.6 News and Social Media Coverage News SentimentNeuroPace has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for NeuroPace this week, compared to 1 article on an average week.MarketBeat Follows2 people have added NeuroPace to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuroPace insiders have not sold or bought any company stock.Percentage Held by Insiders27.50% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.69% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeuroPace are expected to grow in the coming year, from ($1.53) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroPace is -5.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroPace is -5.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroPace has a P/B Ratio of 6.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NeuroPace (NASDAQ:NPCE) StockNeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Read More NPCE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NPCE Stock News HeadlinesSeptember 29, 2023 | americanbankingnews.comContrasting Apyx Medical (NASDAQ:APYX) and NeuroPace (NASDAQ:NPCE)September 26, 2023 | americanbankingnews.comNeuroPace (NASDAQ:NPCE) Trading Up 1.8%October 1, 2023 | Oxford Club (Ad)Better Than Oil StocksThe best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 20, 2023 | finance.yahoo.comNeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare ConferenceAugust 25, 2023 | msn.comMorgan Stanley Upgrades NeuroPace (NPCE)August 24, 2023 | finance.yahoo.comNeuroPace to Participate in Upcoming Investor ConferencesAugust 13, 2023 | finance.yahoo.comRainbows and Unicorns: NeuroPace, Inc. (NASDAQ:NPCE) Analysts Just Became A Lot More OptimisticAugust 9, 2023 | finanznachrichten.deNeuroPace, Inc.: NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue GuidanceOctober 1, 2023 | Oxford Club (Ad)Better Than Oil StocksThe best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. August 8, 2023 | finance.yahoo.comNeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue GuidanceJuly 19, 2023 | finance.yahoo.comNeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock MarketJuly 18, 2023 | finance.yahoo.comNeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023June 29, 2023 | finanznachrichten.deNeuroPace, Inc.: NeuroPace Announces CEO TransitionJune 28, 2023 | finance.yahoo.comNeuroPace Announces CEO TransitionJune 14, 2023 | benzinga.comPeople Are Lining Up For Elon Musk's Neuralink Brain Implant — Here's How You Can Invest In Brain Technology StartupsMay 25, 2023 | finanznachrichten.deNeuroPace, Inc.: NeuroPace Announces Addition of Kelley Nicholas as Vice President, SalesMay 24, 2023 | finance.yahoo.comNeuroPace Announces Addition of Kelley Nicholas as Vice President, SalesMay 18, 2023 | msn.comNeuroPace's Return On Capital Employed OverviewMay 6, 2023 | msn.comMorgan Stanley Maintains NeuroPace (NPCE) Underweight RecommendationMay 5, 2023 | msn.comRecap: NeuroPace Q1 EarningsMay 4, 2023 | finance.yahoo.comNeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue GuidanceApril 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT) and NeuroPace (NPCE)April 17, 2023 | finance.yahoo.comNeuroPace to Report First Quarter 2023 Financial Results on May 4, 2023April 17, 2023 | finance.yahoo.comFurther Upside For NeuroPace, Inc. (NASDAQ:NPCE) Shares Could Introduce Price Risks After 39% BounceApril 3, 2023 | finance.yahoo.comNeuroPace to Present at the 22nd Annual Needham Virtual Healthcare ConferenceMarch 30, 2023 | finance.yahoo.comNeuroPace (NASDAQ:NPCE) adds US$17m to market cap in the past 7 days, though investors from a year ago are still down 44%March 6, 2023 | finance.yahoo.comNeuroPace, Inc. (NASDAQ:NPCE) Q4 2022 Earnings Call TranscriptSee More Headlines Receive NPCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter. Email Address NPCE Company Calendar Last Earnings8/08/2023Today10/01/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NPCE CUSIPN/A CIK1528287 Webwww.neuropace.com Phone650-237-2700FaxN/AEmployees169Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside-17.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,080,000.00 Net Margins-77.25% Pretax Margin-77.25% Return on Equity-133.74% Return on Assets-38.30% Debt Debt-to-Equity Ratio2.58 Current Ratio7.52 Quick Ratio6.65 Sales & Book Value Annual Sales$54.93 million Price / Sales4.58 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book6.95Miscellaneous Outstanding Shares25,860,000Free Float18,749,000Market Cap$251.62 million OptionableNot Optionable Beta1.97 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Irina Ridley (Age 37)Chief Legal Officer & Corp. Sec. Comp: $499.31kDr. Martha J. Morrell (Age 66)Chief Medical Officer Comp: $555.87kMr. Joel D. Becker (Age 55)CEO & Director Ms. Rebecca L. Kuhn (Age 62)CFO, VP of Fin. & Admin. and Assistant Sec. Ms. Kelley NicholasVP of SalesMs. Irene Thomas (Age 54)VP of HR Mr. Andre G. MarquetteChief Commercial OfficerMore ExecutivesKey CompetitorsTELA BioNASDAQ:TELALyra TherapeuticsNASDAQ:LYRAProfound MedicalNASDAQ:PROFQuipt Home MedicalNASDAQ:QIPTPulse BiosciencesNASDAQ:PLSEView All CompetitorsInsiders & InstitutionsKent Lake Capital LLCBought 21,529 shares on 8/15/2023Ownership: 0.577%BlackRock Inc.Bought 3,646 shares on 8/11/2023Ownership: 0.140%Renaissance Technologies LLCBought 2,800 shares on 8/11/2023Ownership: 0.067%Accelmed Partners Ii L.P.Bought 327,893 shares on 11/21/2022Total: $491,839.50 ($1.50/share)View All Insider TransactionsView All Institutional Transactions NPCE Stock - Frequently Asked Questions Should I buy or sell NeuroPace stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NPCE shares. View NPCE analyst ratings or view top-rated stocks. What is NeuroPace's stock price forecast for 2023? 2 equities research analysts have issued 1 year price targets for NeuroPace's shares. Their NPCE share price forecasts range from $6.00 to $10.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests that the stock has a possible downside of 17.8%. View analysts price targets for NPCE or view top-rated stocks among Wall Street analysts. How have NPCE shares performed in 2023? NeuroPace's stock was trading at $1.49 at the beginning of the year. Since then, NPCE shares have increased by 553.0% and is now trading at $9.73. View the best growth stocks for 2023 here. Are investors shorting NeuroPace? NeuroPace saw a drop in short interest in September. As of September 15th, there was short interest totaling 352,200 shares, a drop of 20.2% from the August 31st total of 441,100 shares. Based on an average daily trading volume, of 72,200 shares, the short-interest ratio is currently 4.9 days. Currently, 3.3% of the company's shares are short sold. View NeuroPace's Short Interest. When is NeuroPace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our NPCE earnings forecast. How were NeuroPace's earnings last quarter? NeuroPace, Inc. (NASDAQ:NPCE) issued its earnings results on Tuesday, August, 8th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.11. The firm had revenue of $16.51 million for the quarter, compared to analysts' expectations of $12.74 million. NeuroPace had a negative net margin of 77.25% and a negative trailing twelve-month return on equity of 133.74%. What guidance has NeuroPace issued on next quarter's earnings? NeuroPace issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $59.00 million-$61.00 million, compared to the consensus revenue estimate of $52.85 million. When did NeuroPace IPO? (NPCE) raised $85 million in an initial public offering on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers. What is NeuroPace's stock symbol? NeuroPace trades on the NASDAQ under the ticker symbol "NPCE." How do I buy shares of NeuroPace? Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NeuroPace's stock price today? One share of NPCE stock can currently be purchased for approximately $9.73. How much money does NeuroPace make? NeuroPace (NASDAQ:NPCE) has a market capitalization of $251.62 million and generates $54.93 million in revenue each year. The company earns $-47,080,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. How many employees does NeuroPace have? The company employs 169 workers across the globe. How can I contact NeuroPace? The official website for the company is www.neuropace.com. The company can be reached via phone at 650-237-2700 or via email at investors@neuropace.com. This page (NASDAQ:NPCE) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.